Education
About Us
Working with TipRanks
Follow Us
Vivesto AB (SE:VIVE)
:VIVE
VIVE Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr0.20 - kr0.40
Previous CloseN/A
Volume772.68K
Average Volume (3M)303.74K
Market Cap
kr123.75M
Enterprise ValueN/A
Total Cash (Recent Filing)kr102.23M
Total Debt (Recent Filing)kr6.98M
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
Aug 12, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding538,043,460
10 Day Avg. Volume374,994
30 Day Avg. Volume303,738
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-1.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vivesto AB News
VIVE FAQ
What was Vivesto AB’s price range in the past 12 months?
Vivesto AB lowest stock price was kr0.20 and its highest was kr0.40 in the past 12 months.
What is Vivesto AB’s market cap?
Vivesto AB’s market cap is kr123.75M.
When is Vivesto AB’s upcoming earnings report date?
Vivesto AB’s upcoming earnings report date is Aug 12, 2025 which is in 69 days.
How were Vivesto AB’s earnings last quarter?
Vivesto AB released its earnings results on May 08, 2025. The company reported -kr0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.015.
Is Vivesto AB overvalued?
According to Wall Street analysts Vivesto AB’s price is currently Overvalued.
Does Vivesto AB pay dividends?
Vivesto AB does not currently pay dividends.
What is Vivesto AB’s EPS estimate?
Vivesto AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB have?
Vivesto AB has 538,043,460 shares outstanding.
What happened to Vivesto AB’s price movement after its last earnings report?
Vivesto AB reported an EPS of -kr0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.979%.
Which hedge fund is a major shareholder of Vivesto AB?
Currently, no hedge funds are holding shares in SE:VIVE
Company Description
Vivesto AB
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Technical Analysis
Elicera Therapeutics AB
―
Active Biotech AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―